- Doctors now know which patients face the highest heart risks from a common breast cancer drug
- Helps women with HER2-positive breast cancer stay safe during life-saving treatment
- Not a new treatment — but a smarter way to prevent harm before it starts
This could help doctors protect patients’ hearts before cancer therapy even begins.
She’s 62, just diagnosed with HER2-positive breast cancer. The plan: start trastuzumab — a powerful drug that targets her cancer. But there’s a risk. The very medicine that could save her life might also hurt her heart.
She’s not alone.
HER2-positive breast cancer affects about 1 in 5 breast cancer patients. Trastuzumab has changed outcomes — many live longer, healthier lives because of it.
But it comes with a hidden cost.
Some patients develop cardiotoxicity — a drop in heart function that can lead to heart failure. It doesn’t always cause symptoms at first. By the time it’s caught, damage may already be done.
Right now, all patients are monitored. But not everyone is at equal risk.
And until now, it hasn’t been clear who needs extra protection — and who doesn’t.
The Hidden Risk Pattern
For years, doctors assumed heart problems from trastuzumab were mostly random.
Sure, older patients or those with past heart issues seemed more vulnerable. But no clear pattern emerged.
But here’s the twist: this study found five strong, predictable warning signs.
And they can be checked before treatment starts.
Five Flags That Raise Risk
The study looked at 298 women taking trastuzumab.
21.8% — about 1 in 5 — developed heart damage.
After analyzing age, health history, lab tests, and heart scans, researchers found five key red flags:
- Age 60 or older
- History of high blood pressure
- Received anthracycline chemo before or with trastuzumab
- High levels of a heart stress marker (NT-proBNP ≥200 pg/ml)
- Lower-than-normal heart pumping strength (LVEF ≤55%)
Each factor nearly doubles the risk. But together? The danger grows much more.
Your Heart’s Warning System
Think of NT-proBNP like a smoke alarm for your heart.
When heart muscle is strained, it releases this protein. High levels mean the heart is under stress — even if you feel fine.
LVEF is like a fuel gauge. It shows how well your heart pumps blood. Normal is 55% or higher. Below that? The engine’s not running at full power.
Why This Changes Things
In the past, monitoring was one-size-fits-all.
Now, doctors can use these five signs to sort patients into risk levels.
Low risk? Standard checks may be enough.
High risk? They might start heart-protecting drugs early, adjust chemo timing, or monitor more closely.
It’s not about stopping cancer treatment. It’s about making it safer.
This doesn’t mean this treatment is available yet.
Women with all five risk factors were up to three times more likely to develop heart problems.
The biggest single risk? Having had anthracycline chemo — a common earlier treatment. It raises the odds by more than 3-fold.
But even without that, high NT-proBNP or low LVEF still doubled the risk.
These aren’t rare cases. Many patients have at least one of these signs.
The Real-World Impact
Imagine two women starting trastuzumab.
One is 48, healthy, normal heart tests, no high blood pressure.
Her risk is low. She can start treatment with confidence.
The other is 65, had anthracycline chemo, and her pre-treatment scan shows an LVEF of 50%.
She’s at high risk.
Now, her care team can act before damage occurs — maybe starting a blood pressure drug known to protect the heart, or scheduling more frequent heart scans.
But there’s a catch.
This isn’t a one-off finding. It fits a growing trend: personalized safety in cancer care.
We’ve focused for years on making treatment stronger. Now, we’re learning to make it smarter.
By using simple, available tests, we can predict risk — not wait for damage to show up.
That’s a shift from reaction to prevention.
If you or a loved one is starting trastuzumab, ask your doctor:
- What’s my heart risk?
- Have you checked my NT-proBNP and LVEF?
- Do I have any of these five risk factors?
These tests are routine in many centers. They’re not experimental.
And knowing your risk could change how you’re monitored.
The Fine Print
This study looked back at medical records — it didn’t test a new plan in real time.
Most patients were from one hospital. Results may vary in other groups.
And while the risk factors are clear, we still need studies to prove that acting on them actually prevents heart damage.
So far, it makes sense. But it’s not yet standard practice.
What Comes Next
Researchers want to build a simple risk score — like a calculator doctors can use before treatment.
Then, test whether giving heart meds early to high-risk patients reduces harm.
That kind of trial takes time. But the path is clear.
The goal: no woman has to choose between surviving cancer and protecting her heart.
With better warnings, we may soon prevent heart damage before it starts.
